Updates shares, adds investor letter, company response.  Indivior PLC (NASDAQ:INDV) soared 13% amid some takeover speculation ...

With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, ...

Indivior Plc has entered into a refinancing agreement that would allow it to push back the maturity on its existing term loan ...

Investment fund Oaktree Capital Management has written to Indivior urging the opioid addiction treatment maker to refresh its ...

Indivior (GB:INDV) has released an update. Indivior PLC is actively engaging with Oaktree Capital Management to explore proposals aimed at ...

Investment fund Oaktree Capital Management has urged British drugmaker Indivior to cooperate with the fund in refreshing its ...

M&G Plc lowered its stake in shares of Indivior PLC (NASDAQ:INDV – Free Report) by 6.4% during the third quarter, according to the company in its most recent disclosure with the Securities and ...

Indivior, whose opioid addiction drug is made available by the U.S. Criminal Justice System (CSJ) for the rehabilitation of drug users, said the timing of funding among certain CJS accounts was ...

Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ...

Oaktree believes Indivior should not have waited for seven years after Sublocade's initial FDA approval, and more than a year after its competitor's entry into the market, before submitting its prior ...

Addiction treatment specialist Indivior reported a strong third-quarter performance on Thursday, with total net revenue ...

Indivior PLC (NASDAQ:INDV) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus estimate for Q3 2024 revenue ...